Cytos Biotechnology appoints Itin as CEO

Friday, October 12, 2012 02:29 PM

Cytos Biotechnology, a Swiss biotech company focused on the development of CYT003 in allergic asthma, has appointed Dr. Christian Itin as chief executive officer. The board of directors will propose to the company's shareholders that Itin be elected as member of the board, and it is intended that he will become chairman.

Itin is the former president and CEO of Micromet, a previously Nasdaq-listed biopharmaceutical company, with headquarters in the U.S. and an R&D center in Germany. He led Micromet as CEO from 2004 until its acquisition by Amgen for $1.2 billion in March 2012. In total, Itin has spent 13 years in senior management roles at Micromet. Prior to joining Micromet in 1999, he co-founded Zyomyx, a protein chip company based in Hayward, Calif.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs